Articles tagged "Rejection"

2022 American Transplant Congress
Establishment And Validation Of A Predictive Model For Differential Rejection Diagnosis By Gene Expression Profiling (GEP) In Renal Allograft Biopsies Using Banff Human Organ Transplant (B-HOT) Gene Panel
H. Zhang¹, R. Haun², F. Collin¹, C. Cassol², S. Coley², J. Wilson², S. Stone¹, K. Qu¹, W. Tian¹, N. Agrawal¹, G. Shekhtman¹, C. Larsen²
¹CareDx, Inc., Brisbane, CA, ²Arkana Laboratories, Little Rock, AR
*Purpose: Large scale GEP studies evaluating the performance of Banff-endorsed B-HOT gene panel for allograft rejection diagnosis have not been published. In this study, we…
2022 American Transplant Congress
An Initial Analysis of Baseline Levels of Dd-cfdna After Pancreas Transplantation: A Prospective Study from High-Volume Centers in the United States
A. Yoo¹, I. Qian¹, A. Riedel¹, G. Kibria¹, A. Bartosic¹, R. Soltani², O. Nduanya³, M. Omidi³, J. S. Odorico², P. L. Abrams³, M. Cooper³, J. S. Bromberg¹, J. R. Scalea¹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Wisconsin School of Medicine, Madison, WI, ³Georgetown University School of Medicine, Washington, DC
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) testing, which has been validated for monitoring kidney transplant (KTx) rejection, may provide an alternative to pancreas biopsy that prevents…
2022 American Transplant Congress
Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence
J. Kwon
Surgery, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…
2022 American Transplant Congress
The Impact of T-Cell Receptor Diversity in Acute Kidney Transplant Rejection
T. Sigdel¹, P. Fields², J. Liberto¹, I. Damm¹, M. Kerwin¹, j. Hood², P. Towfighi¹, M. Sirota¹, H. Robins², M. M. Sarwal¹
¹UCSF, San Francisco, CA, ²Adaptive Biotechnologies, Seattle, WA
*Purpose: Recent developments in T-cell receptor (TCR) immunosequencing allow for analysis of alloreactive human T-cell populations both before and after engraftment. In this study, we…
2022 American Transplant Congress
The Pre-Transplant Non-HLA Antibody Burden Predicts the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation
A. Senev¹, B. Ray², J. Hariharan², C. Heylen², M. Emonds¹, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²Immucor Inc.,, Norcross, GA
*Purpose: Many kidney allografts fail due to the occurrence of antibody-mediated rejection (ABMR), related to donor-specific anti-HLA antibodies (HLA-DSA). However, the histology of ABMR can…
2022 American Transplant Congress
Longitudinal Analysis of the Gut Microbiota Structure and Function After Renal Transplantation
A. Vaitkute¹, F. Yuen Chang¹, A. Greco², S. Chong¹, H. Mahdi³, M. Bajaj-Elliott², A. Pesenacker¹, R. Motallebzadeh¹
¹Institute of Immunity and Transplantation, UCL, London, United Kingdom, ²Institute of Child Health, UCL, London, United Kingdom, ³Department of Renal Medicine, UCL, London, United Kingdom
*Purpose: Despite marked improvements in outcomes after renal transplantation, graft loss from alloimmune pathology and adverse side effects including urinary tract infections and diarrhoea remain…
2022 American Transplant Congress
Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group
H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra
Department of Transplant Surgery, Royal Liverpool University Hospital, Liverpool, United Kingdom
*Purpose: The present study investigated the short-term biopsy-proven acute rejection rates and viral infection rates amongst our protocol of single-dose Alemtuzemab (Cohort 1) versus double…
2022 American Transplant Congress
Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial
N. Wilson¹, S. R. Reese², L. Ptak³, F. Aziz², S. Parajuli², V. Jucaud⁴, S. Denham⁴, A. Mishra⁵, P. Hematti⁵, A. Djamali²
¹University of Wisconsin, Madison, WI, ²Medicine, University of Wisconsin, Madison, WI, ³Administration, University of Wisconsin, Madison, WI, ⁴Terasaki Institute, Los Angeles, CA, ⁵UW Comprehensive Cancer Center, University of Wisconsin, Madison, WI
*Purpose: Ixazomib is a second-generation oral proteasome inhibitor, FDA approved for the treatment of refractory multiple myeloma. The purpose of the study was (1) to…
2022 American Transplant Congress
Acute Cellular Rejection in Liver Transplant Recipients Following Vaccination Against Covid-19
R. Sarwar¹, O. Adeyi², N. Lim¹
¹Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, ²Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
*Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has seen the development of effective vaccines in record time. We report a series of five liver…
2022 American Transplant Congress
Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of T-cell Mediated Rejection in Kidney Transplant Biopsies
D. Kumar¹, I. Moinuddin¹, L. Kamal¹, M. Shinbashi¹, N. Raju¹, R. Minniti¹, F. Moran¹, P. Halloran², G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²University of Alberta, Edmonton, AB, Canada
*Purpose: We have reported the correlation of donor-derived cell-free DNA (dd-cfDNA) with histologic and molecular diagnosis (MMDx) of kidney transplant biopsies (Gupta et al, Transplantation…